Lake Street Advisors Group LLC Buys 317 Shares of Boston Scientific Co. (NYSE:BSX)

Lake Street Advisors Group LLC lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 4.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 7,629 shares of the medical equipment provider’s stock after purchasing an additional 317 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Boston Scientific were worth $681,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in BSX. MONECO Advisors LLC increased its position in shares of Boston Scientific by 7.6% during the third quarter. MONECO Advisors LLC now owns 3,861 shares of the medical equipment provider’s stock valued at $324,000 after buying an additional 272 shares during the period. Jacobsen Capital Management boosted its position in shares of Boston Scientific by 4.9% in the third quarter. Jacobsen Capital Management now owns 2,820 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 133 shares during the period. Highview Capital Management LLC DE grew its stake in Boston Scientific by 17.2% during the third quarter. Highview Capital Management LLC DE now owns 23,068 shares of the medical equipment provider’s stock valued at $1,933,000 after acquiring an additional 3,388 shares in the last quarter. Adams Diversified Equity Fund Inc. bought a new stake in Boston Scientific during the 3rd quarter worth approximately $17,908,000. Finally, Golden State Equity Partners lifted its stake in Boston Scientific by 1.4% in the 3rd quarter. Golden State Equity Partners now owns 10,614 shares of the medical equipment provider’s stock worth $889,000 after purchasing an additional 151 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.9 %

BSX opened at $101.61 on Thursday. Boston Scientific Co. has a 12 month low of $65.52 and a 12 month high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The business’s 50-day moving average price is $98.73 and its 200-day moving average price is $89.95. The company has a market cap of $149.96 billion, a P/E ratio of 81.29, a P/E/G ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares in the company, valued at $2,660,580.24. The trade was a 19.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 144,305 shares of company stock worth $14,954,985 in the last three months. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BSX. Stifel Nicolaus boosted their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Piper Sandler raised their price target on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Morgan Stanley boosted their price objective on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Finally, Royal Bank of Canada upped their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.